Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + nab paclitaxel
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Bevacizumab + nab paclitaxel is a combination therapy consisting of two agents with complementary mechanisms of action, used primarily in the treatment of various advanced solid tumors. Bevacizumab is a recombinant humanized monoclonal antibody that targets and neutralizes vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis—the formation of new blood vessels essential for tumor growth and metastasis[4][8]. Nab-paclitaxel is an albumin-bound formulation of the cytotoxic agent paclitaxel, designed to enhance drug delivery to tumors by exploiting albumin-mediated transport pathways and reducing hypersensitivity reactions associated with solvent-based formulations[4][5][7]. Nab-paclitaxel disrupts microtubule function, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. The combination has been investigated in multiple phase II studies for diseases such as platinum-resistant ovarian cancer, metastatic neuroendocrine carcinoma, and advanced non-small cell lung cancer (NSCLC), among others[1][3][4]. This regimen aims to leverage antiangiogenic effects from bevacizumab alongside direct cytotoxicity from nab-paclitaxel.
- Brand names
- Abraxane (nab-paclitaxel)Avastin (bevacizumab)
- Other names
- albumin-bound paclitaxel + bevacizumabnab-paclitaxel + bevacizumab
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + nab paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + nab paclitaxel.